A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and design-Reference-Cited by-同舟云学术

A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and design

Published:2019-09-05 Issue:1 Volume:270 Page:83-94
ISSN:0940-1334
Container-title:European Archives of Psychiatry and Clinical Neuroscience
language:en
Short-container-title:Eur Arch Psychiatry Clin Neurosci

Author:

Schmidt-Kraepelin Christian,Feyerabend Sandra,Engelke Christina,Riesbeck Mathias,Meisenzahl-Lechner Eva,Gaebel Wolfgang,Verde Pablo-Emilio,Kolbe Henrike,Correll Christoph U.,Leucht Stefan,Heres Stephan,Kluge Michael,Makiol Christian,Neff Andrea,Lange Christina,Englisch Susanne,Zink Mathias,Langguth Berthold,Poeppl Timm,Reske Dirk,Gouzoulis-Mayfrank Euphrosyne,Gründer Gerhard,Hasan Alkomiet,Brockhaus-Dumke Anke,Jäger Markus,Baumgärtner Jessica,Wobrock Thomas,Cordes Joachim

Funder

German Federal Ministry of Education and Research

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Biological Psychiatry,Psychiatry and Mental health,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00406-019-01063-4.pdf

Reference68 articles.

1. Howes OD, McCutcheon R, Agid O, De Bartolomeis A, Van Beveren NJ, Birnbaum ML, Bloomfield MA, Bressan RA, Buchanan RW, Carpenter WT (2016) Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry 174(3):216–229

2. Carbon M, Correll CU (2014) Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues clin neurosci 16(4):505

3. Carbon M, Kane JM, Leucht S, Correll CU (2018) Tardive dyskinesia risk with first-and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. World Psychiatry 17(3):330–340